MannKind Q1 Revenues Rise 15% to $90.2M; PDUFA Dates for Afrezza Pediatric and Furoscix ReadyFlow
MannKind reported Q1 2026 revenues of $90.2M, up 15% year-over-year on $15.5M in Furoscix net sales (64% dose growth) and $32.7M in royalties. The company settled $36.3M of convertible notes, received $5M from United Therapeutics for ralinepag DPI and targets PDUFA dates of May 29 and July 26.
1. Financial Results
MannKind posted total Q1 2026 revenues of $90.2 million, a 15% increase from $78.4 million a year earlier. Growth was driven by $15.5 million in Furoscix net sales (a 64% rise in doses dispensed), $15.3 million in Afrezza sales and $32.7 million in royalty income.
2. Commercial Portfolio Updates
Furoscix delivered $15.5 million in net sales in Q1 and awaits FDA action on its ReadyFlow Autoinjector on July 26, 2026. Afrezza inhaled insulin generated $15.3 million in net sales and the pediatric indication has a PDUFA target date of May 29, 2026.
3. Pipeline Developments
Nintedanib DPI (MNKD-201) advanced toward a Phase 2 idiopathic pulmonary fibrosis trial with first patient enrollment expected in Q2 2026. United Therapeutics collaboration on ralinepag DPI garnered a $5 million upfront payment and could yield up to $35 million in milestones plus 10% royalties.
4. Corporate and Capital Structure
Cash and investments totaled $134 million as of March 31, 2026. MannKind settled $36.3 million of 2.50% senior convertible notes for $35.5 million in cash and 569,023 shares of common stock, strengthening its balance sheet.